AGIO
Agios Pharmaceuticals, Inc.
There isn't enough reported data to score AGIO yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
AGIO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
AGIO's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AGIO PE Valuation
AGIO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AGIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect AGIO's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
AGIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$6.33 | +$0.37 |
| Q2 2026 | -$7.02 | -162% |
| Q1 2026 | -$7.26 | -163% |
| Q4 2025 | -$7.12 | -161% |
| Q3 2025 | -$6.70 | -159% |
| Q2 2025 | $11.30 | +$17.79 |
| Q1 2025 | $11.54 | +$17.85 |
| Q4 2024 | $11.64 | +$17.97 |
AGIO lost $6.33 per share over the past year, about the same as its loss the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over AGIO on earnings quality, reporting a profit while its opponent remains loss making.
AGIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $55.4M | +330% |
| Q2 2026 | $44.7M | +259% |
| Q1 2026 | $20.7M | +138% |
| Q4 2025 | $20M | +86% |
| Q3 2025 | $12.9M | +44% |
| Q2 2025 | $12.5M | +45% |
| Q1 2025 | $8.7M | +6.6% |
| Q4 2024 | $10.7M | +51% |
AGIO has the edge over LLY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -139% | +768 points |
| Q2 2026 | -247% | +773 points |
| Q1 2026 | -530% | +692 points |
| Q4 2025 | -609% | +556 points |
| Q3 2025 | -907% | +240 points |
| Q2 2025 | -1020% | +208 points |
| Q1 2025 | -1222% | -98 points |
| Q4 2024 | -1165% | +331 points |
AGIO's operating margin was −139% last quarter, up 768 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over AGIO on profitability, with a higher operating margin.
AGIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$60.4M | +$29.3M |
| Q2 2026 | -$58.5M | +$19.5M |
| Q1 2026 | -$119.7M | -$7.4M |
| Q4 2025 | -$97.3M | +$36.8M |
| Q3 2025 | -$89.7M | -$5.1M |
| Q2 2025 | -$78M | -$5.3M |
| Q1 2025 | -$112.3M | -$12.2M |
| Q4 2024 | -$134.1M | -$61.4M |
AGIO has burned cash in almost every quarter: −$336M over the past year, against −$414M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over AGIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
AGIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +219K shares |
| 1 year | +2.7% | +1.6M shares |
| 3 years | +7% | +3.9M shares |
| 5 years | +4.7% | +2.7M shares |
| Available history | -0.5% | -287K shares |
AGIO has 60M diluted shares, up 2.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q4 2021 | $19M |
| Q3 2021 | $254.4M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AGIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AGIO Net Leverage
AGIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
AGIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.7 | Neutral |
| Stochastic | 23.0 | Neutral |
AGIO's weekly RSI is 49 (neutral) and its Stochastic is 23 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AGIO PE vs Healthcare Sector
| Metric | AGIO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AGIO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AGIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $32.0 | 0.8% below |
| 20 week MA | $33.7 | 5.6% below |
| 50 week MA | $30.9 | 2.7% above |
| 100 week MA | $32.8 | 3.1% below |
| 200 week MA | $32.4 | 1.9% below |
AGIO's trend is mixed: it's above one of its five weekly moving averages, and 1.9% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over AGIO on trend strength, trading above more of its moving averages.
AGIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.5 | $45.2 | -6.9% |
| 2021 | $45.2 | $35.8 | -21% |
| 2022 | $35.8 | $27.0 | -25% |
| 2023 | $27.0 | $22.3 | -18% |
| 2024 | $22.3 | $33.4 | +50% |
| 2025 | $33.4 | $28.0 | -16% |
| 2026 YTD | $28.0 | $31.8 | +13% |
AGIO has finished lower in five of the last six years. It's up 13% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AGIO on returns for 2026, with the stronger performance.